Tarsus Pharmaceuticals (TARS) Net Income towards Common Stockholders (2019 - 2026)

Tarsus Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$6.9 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 72.33% year-over-year to -$6.9 million in Q1 2026; TTM through Mar 2026 was -$149.5 million, a 45.27% decrease from a year earlier, with the FY2025 full-year figure at -$66.4 million, up 42.52% from the prior year.
• Net Income towards Common Stockholders fell to -$6.9 million in Q1 2026 per TARS's latest filing, from -$6.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$5.5 million in Q2 2022 and bottomed at -$123.7 million in Q2 2025.
• The 5-year median for Net Income towards Common Stockholders is -$23.3 million (2023), against an average of -$28.5 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 474.12% in 2023 and surged 73.03% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$13.1 million in 2022, then plunged by 224.08% to -$42.5 million in 2023, then jumped by 45.51% to -$23.1 million in 2024, then jumped by 73.03% to -$6.2 million in 2025, then retreated by 11.03% to -$6.9 million in 2026.
• Per Business Quant, the three latest TARS Net Income towards Common Stockholders figures stand at -$6.9 million (Q1 2026), -$6.2 million (Q4 2025), and -$12.7 million (Q3 2025).